Alkermes PLC (ALKS)
| Market Cap | 3.03B |
| Revenue (ttm) | 1.04B |
| Net Income (ttm) | -110.86M |
| Shares Out | 158.80M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | 39.68 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $19.04 |
| Previous Close | $19.44 |
| Change ($) | -0.40 |
| Change (%) | -2.06% |
| Day's Open | 19.46 |
| Day's Range | 18.52 - 19.91 |
| Day's Volume | 1,719,780 |
| 52-Week Range | 11.98 - 23.92 |
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the ...
DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual...
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over ...
DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Applicatio...
Alkermes (ALKS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alkermes' (ALKS) Value Enhancement Plan is set to drive growth, improve operational and financial performance, as well as enhance shareholder value.
DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance...
Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding i...
Alkermes plc (ALKS) CEO Richard Pops on Q3 2020 Results - Earnings Call Transcript
Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical di...
Alkermes (ALKS) delivered earnings and revenue surprises of 2700.00% and 11.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year 2020....
DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss th...
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...
Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.
An FDA joint committee's favorable votes on an Alkermes drug candidate to treat bipolar I and schizophrenia came just weeks ahead of an expected key FDA decision and sent ALKS stock rising. Th...
DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Dru...
DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopha...
DUBLIN, Oct. 7, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2...
DUBLIN, Sept. 18, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered...
DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at...
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-...
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S.
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
DUBLIN, Aug. 19, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 423...
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
Alkermes plc (ALKS) CEO Richard Pops on Q2 2020 Results - Earnings Call Transcript
Alkermes (ALKS) delivered earnings and revenue surprises of 700.00% and 3.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Alkermes (NASDAQ:ALKS) rose 2.5% in pre-market trading after the company reported Q2 results.
DUBLIN, July 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2020 and provided updated financial expectations for full-year 2020...
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
DUBLIN, June 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1,...
DUBLIN, June 24, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special ed...
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DUBLIN, June 4, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conferen...
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
DUBLIN, May 27, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new research from its schizophrenia portfolio at the American Society of Clinical Psychopharma...
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop... [Read more...]
| Industry Biotechnology | IPO Date Jul 16, 1991 |
| CEO Richard F. Pops | Employees 2,245 |
| Stock Exchange NASDAQ | Ticker Symbol ALKS |
Financial Performance
In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.
Analyst Forecasts
According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 21.89, which is an increase of 14.97% from the latest price.